Impact of Transcranial Direct Current Stimulation in Pain, Fatigue, and Health Quality of Life of Patients with Idiopathic Inflammatory Myopathies: A Randomized, Double-Blind, Sham-Controlled Crossover Clinical Trial
Table 1
Data related to anthropometric, demographic, comorbidities, physical activity levels, pharmacological therapy, and other drugs of the patients with systemic autoimmune myopathies.
tDCS ()
Sham ()
value
Demographic and anthropometric
Age (years)
0.952
Female sex (%)
15 (93.7)
14.0 (93.0)
0.943
White ethnicity (%)
8 (50.0)
10.0 (66.6)
0.564
Weight (kg)
0.921
Body mass index (kg/m2)
0.950
Comorbidities
Systemic arterial hypertension (%)
7 (43.7)
7 (46.6)
0.185
Dyslipidemia (%)
5 (31.2)
6 (40.0)
0.894
Diabetes mellitus (%)
3 (18.7)
3 (20.0)
0.126
Depression (%)
0
0
>0.999
Physical activity levels
Low (%)
11 (68.7)
12 (80.0)
0.669
Moderate (%)
3 (18.7)
3 (20.0)
0.464
High (%)
2 (12.5)
0
0.263
Equivalent for the task (weekly)
478 (209-1099)
132 (0.0-378)
0.043
Pharmacological therapy
Glucocorticoids (%)
6 (37.5)
8 (53.3)
0.600
Daily dosage (mg)
0.0 (0.0-8.0)
5.0 (0.0-17.0)
0.731
IS/IM (%)
10 (62.5)
12 (80.0)
0.498
Leflunomide (%)
3 (18.7)
3 (20.0)
0.126
Methotrexate (%)
5 (31.2)
7 (46.6)
0.608
Azathioprine (%)
2 (12.5)
3 (20.0)
0.932
Mycophenolate of mofetil (%)
6 (37.5)
4 (26.6)
0.810
Rituximab (%)
0
0
>0.999
Other drugs
Antihypertensive (%)
5 (31.2)
4 (26.6)
0.443
Pain relievers (%)
4 (25.0)
4 (26.6)
0.647
Statins (%)
1 (6.2)
3 (20.0)
0.545
Antidepressants (%)
0
0
>0.999
Data presented as deviation, median (25th-75th), or frequency (%). IM: immunomodulators; IS: immunosuppressants; tDCS: transcranial direct current stimulation.
